6 Jun 2023
In this video, Dr. Garry Pairaudeau, CTO of Exscientia, discusses the company’s AI-driven drug discovery platform. Designed to automate drug discovery and development, explore how this end-to-end pipeline is helping to generate new medicines quickly and efficiently.
Exscientia
Garry joined Exscientia following an impactful career at AstraZeneca where he combined drug hunting and technology leadership. In his role as Vice President of Hit Discovery and Chair of the Global Chemistry Leaders Network, he led high-throughput Screening, DNA encoded library screening and virtual screening. He was also responsible for many strategic initiatives, championing AstraZeneca’s developments in artificial intelligence, machine learning, and physics-based computational methods, ultimately leading to AstraZeneca's “Augmented Drug Design” programme. Garry also established an automation facility in Gothenburg, dedicated to synthesis and integrated screening. He has a passion for efficient drug discovery and constantly strives for new, innovative ways to drive projects forward to discover high quality candidates. Garry obtained his Ph.D. in organic Chemistry from the University of Southampton.